Literature DB >> 8852456

Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis.

V Preac Mursic1, W Marget, U Busch, D Pleterski Rigler, S Hagl.   

Abstract

For a better understanding of the persistence of Borrelia burgdorferi sensu lato (s.l.) after antibiotic therapy the kinetics of killing B. burgdorferi s.l. under amoxicillin, doxycycline, cefotaxime, ceftriaxone, azithromycin and penicillin G were determined. The killing effect was investigated in MKP medium and human serum during a 72 h exposure to antibiotics. Twenty clinical isolates were used, including ten strains of Borrelia afzelii and ten strains of Borrelia garinii. The results show that the kinetics of killing borreliae differ from antibiotic to antibiotic. The killing rate of a given antibiotic is less dependent on the concentration of the antibiotic than on the reaction time. Furthermore, the data show that the strains of B. afzelii and B. garinii have a different reaction to antibiotics used in the treatment of Lyme borreliosis and that different reactions to given antibiotics also exist within one species. The B. garinii strains appear to be more sensitive to antibiotics used in therapy. Furthermore, the persistence of B. burgdorferi s.l. and clinical recurrences in patients despite seemingly adequate antibiotic treatment is described. The patients had clinical disease with or without diagnostic antibody titers to B. burgdorferi.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852456     DOI: 10.1007/bf01780643

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  31 in total

1.  Spirochetes in the spleen of a patient with chronic Lyme disease.

Authors:  M A Cimmino; A Azzolini; F Tobia; C M Pesce
Journal:  Am J Clin Pathol       Date:  1989-01       Impact factor: 2.493

2.  Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis.

Authors:  J Schmidli; T Hunziker; P Moesli; U B Schaad
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

3.  Cefotaxime versus penicillin in the late stage of Lyme disease--prospective, randomized therapeutic study.

Authors:  D Hassler; L Zöller; M Haude; H D Hufnagel; F Heinrich; H G Sonntag
Journal:  Infection       Date:  1990 Jan-Feb       Impact factor: 3.553

4.  In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents.

Authors:  J M Levin; J A Nelson; J Segreti; B Harrison; C A Benson; F Strle
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

5.  In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.

Authors:  R C Johnson; C Kodner; M Russell
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

6.  Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.

Authors:  H W Pfister; V Preac-Mursic; B Wilske; E Schielke; F Sörgel; K M Einhäupl
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

7.  Molecular characterization of Borrelia burgdorferi sensu lato strains by pulsed-field gel electrophoresis.

Authors:  U Busch; C H Teufel; R Boehmer; B Wilske; V Preac-Mursic
Journal:  Electrophoresis       Date:  1995-05       Impact factor: 3.535

8.  Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study.

Authors:  H W Pfister; V Preac-Mursic; B Wilske; K M Einhäupl
Journal:  Arch Neurol       Date:  1989-11

Review 9.  Isolation techniques for spirochetes and their sensitivity to antibiotics in vitro and in vivo.

Authors:  R C Johnson
Journal:  Rev Infect Dis       Date:  1989 Sep-Oct

10.  Erythema chronicum migrans Afzelius in Sweden. A study on 231 patients.

Authors:  E Asbrink; I Olsson; A Hovmark
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1986-12
View more
  13 in total

Review 1.  Antibiotic treatment of animals infected with Borrelia burgdorferi.

Authors:  Gary P Wormser; Ira Schwartz
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

2.  In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto.

Authors:  Martin Sicklinger; Ralf Wienecke; Uwe Neubert
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

Review 3.  A systematic review of Borrelia burgdorferi morphologic variants does not support a role in chronic Lyme disease.

Authors:  Paul M Lantos; Paul G Auwaerter; Gary P Wormser
Journal:  Clin Infect Dis       Date:  2013-12-12       Impact factor: 9.079

4.  In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy.

Authors:  Klaus-Peter Hunfeld; Eva Ruzic-Sabljic; Douglas E Norris; Peter Kraiczy; Franc Strle
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.

Authors:  P Kraiczy; J Weigand; T A Wichelhaus; P Heisig; H Backes; V Schäfer; G Acker; V Brade; K P Hunfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Relationship between the Borrelia burgdorferi specific immune response and different stages and syndromes in neuroborreliosis.

Authors:  P Oschmann; H J Wellensiek; W Zhong; W Dorndorf; K W Pflughaupt
Journal:  Infection       Date:  1997 Sep-Oct       Impact factor: 3.553

Review 7.  Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.

Authors:  Klaus-Peter Hunfeld; Volker Brade
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

8.  In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.

Authors:  Kristina Morgenstern; Georg Baljer; Douglas E Norris; Peter Kraiczy; Christa Hanssen-Hübner; Klaus-Peter Hunfeld
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

9.  Formation and cultivation of Borrelia burgdorferi spheroplast-L-form variants.

Authors:  V P Mursic; G Wanner; S Reinhardt; B Wilske; U Busch; W Marget
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

10.  Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi.

Authors:  Klaus-Peter Hunfeld; Thomas A Wichelhaus; Rebecca Rödel; Georg Acker; Volker Brade; Peter Kraiczy
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.